Related Experiment Video
Updated: Feb 5, 2026

A Preclinical Murine Model of Hepatic Metastases
Published on: September 27, 2014
Ask the Experts: Management of hepatic metastases from neuroendocrine cancer
1Mayo Clinic, Division of Gastroenterologic and General Surgery, 1216 2nd St SW, Rochester, MN 55902, USA.
Abstract:
David M Nagorney, Professor of Surgery, was born and raised in Kansas City (KS, USA) in the USA. He graduated from the University of Kansas (KS, USA), the University of Kansas Medical School and the Mayo Graduate School of Medicine (MN, USA). He completed his general surgery residency at the Mayo Graduate School of Medicine and served as a research fellow there. He was selected as a Mayo Foundation Scholar and completed his training at the Royal Postgraduate Medical School, Hammersmith Hospital (London, UK). He is an accomplished general surgeon, holding a status of Professor of Surgery, specializing in the treatment of gastroenterologic and liver oncologic diseases at the Mayo Clinic Department of Surgery (MN, USA). Presently, he is the program director for the Mayo Clinic Department of Surgery Fellowship Scholars. Nagorney is a member of numerous national and international surgical societies focusing on hepato-pancreatic-biliary surgery and surgical oncology.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Tonsillitis II: Management
Impression Management Techniques I: Managing Appearances
Hepatic Drug Excretion: Influencing Factors

